A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness and ...

TASS/. The Health Insurance Administration of South China's Hainan Province has temporarily included the country's oral anti-Covid drug Azvudine into the list of medicine covered by medical insurance.

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness ...